Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019
Open Access
- 21 July 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 9 (14), e017529
- https://doi.org/10.1161/jaha.120.017529
Abstract
Atrial fibrillation is a common clinical manifestation in hospitalized coronavirus disease of 2019 (COVID‐19) patients. Medications used to treat atrial fibrillation such as antiarrhythmic drugs and anticoagulants may have significant drug interactions with emerging COVID‐19 treatments. Common unintended non‐therapeutic target effects of COVID‐19 treatment include IKr blockade, CYP450 isoenzyme inhibition or activation, and P‐glycoprotein inhibition. Drug‐drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID‐19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID‐19 patients with concomitant atrial fibrillation.This publication has 67 references indexed in Scilit:
- Antiarrhythmic Drug Therapy for Atrial FibrillationCirculation, 2012
- Inflammatory cytokines and atrial fibrillation: current and prospective viewsJournal of Inflammation Research, 2010
- Azithromycin induces anti-viral responses in bronchial epithelial cellsEuropean Respiratory Journal, 2010
- AntiarrhythmicsClinical Pharmacokinetics, 2007
- Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: A multivariate analysisJournal of the American College of Cardiology, 2004
- ACE2: from vasopeptidase to SARS virus receptorTrends in Pharmacological Sciences, 2004
- Influence of hydroxychloroquine on the bioavailability of oral metoprololBritish Journal of Clinical Pharmacology, 2000
- Action Potential Prolongation Exhibits Simple Dose-Dependence for Sotalol, but ReverseJournal of Cardiovascular Pharmacology, 1993
- Clinical Pharmacokinetics of InterferonsClinical Pharmacokinetics, 1990
- Congestive Heart Failure Caused by Oral DisopyramideThe New England Journal of Medicine, 1980